Trigger OEM Glock Housing SP30275 34 26 19 17 Glock 9mm 4 Gen Fits Ejector with Pistol


  1. Home
  2. Trigger OEM Glock Housing SP30275 34 26 19 17 Glock 9mm 4 Gen Fits Ejector with
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Glock OEM Trigger Housing with Ejector Fits Gen 4 9mm Glock 17 19 26 34 SP30275
Condition: New: A brand-new, unused, unopened, undamaged item in its original packaging (where packaging is For Gun Make: GLOCK
Type: Trigger Parts Modified Item: No
MPN:

SP30275

Custom Bundle: No
For Gun Type: Handgun Specific Part: Trigger Housing w/ Ejector
For Gun Model: Gen 4 9mm - Glock 17, 19, 26, 34 (not G43) Quantity: 13
Brand:

GLOCK

UPC:

Does Not Apply





published on tue nov 09 2021

Trigger OEM Glock Housing SP30275 34 26 19 17 Glock 9mm 4 Gen Fits Ejector with Pistol

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Trigger OEM Glock Housing SP30275 34 26 19 17 Glock 9mm 4 Gen Fits Ejector with Pistol

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS